Business
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from the offering are expected to be $285.0 million before deducting underwriting discounts and commissions and other offering expenses payable by LB Pharmaceuticals. In addition, LB Pharmaceuticals has
About this update from Lb Pharmaceuticals Inc
[{"type":"image","alt":"LB Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"LB Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":208,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/7ec9cdef8e7ca23d2ed6879c46ed3d01"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/mAfHG8UMaaqGe4Sknv3Sdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7ec9cdef8e7ca23d2ed6879c46ed3d01","width":208,"height":200}},"lazy":false},{"type":"text","content":"NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from the offering are expected to be $285.0 million before deducting underwriting discounts and commissions and other offering expenses payable by LB Pharmaceuticals. In addition, LB Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.","length":694,"tagName":"p"},{"type":"text","content":"The shares are expected to begin trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.” The offering is expected to close on September 12, 2025, subject to the satisfaction of customary closing conditions.","length":240,"tagName":"p"},{"type":"text","content":"Leerink Partners, Piper Sandler and Stifel are acting as joint bookrunning managers for this offering.","length":102,"tagName":"p"},{"type":"text","content":"A registration statement on Form S-1, as amended, and an additional registration statement relating to these securities have been filed with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on September 10, 2025. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. The offering is being made only by means of a written prospectus. Copies of the final prospectus, when available, will be filed with the SEC and may be obtained from: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) ...